Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB) from its SEC filings: 2022 revenue $8.1 million (-41% vs the year before), free cash flow -$101.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2022) | $8.1 million |
| Revenue growth | -41% |
| Free cash flow | -$101.0 million |
| Diluted EPS | $-10.10 |
| Cash | $159.4 million |
| Share count, 1 year | +38% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.